Fulcrum Therapeutics
Clinical trials sponsored by Fulcrum Therapeutics, explained in plain language.
-
Hope for FSHD: experimental drug losmapimod put to the test
Disease control TerminatedThis study tested a drug called losmapimod in 76 adults with facioscapulohumeral muscular dystrophy (FSHD), a rare disease that causes muscle weakness. The goal was to see if the drug is safe and can help control the disease. Participants received either losmapimod or a placebo f…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug shows promise for rare muscle disorder in early trial
Disease control TerminatedThis study tested a drug called losmapimod in 14 adults with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a rare genetic condition that causes muscle weakness. The main goal was to see if the drug is safe and tolerable, and to measure changes in certain body markers. Th…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
FSHD drug trial halted: what we learned from losmapimod
Disease control TerminatedThis study tested a drug called losmapimod in 260 adults with a rare muscle disease called FSHD, which causes progressive weakness. Participants took either the drug or a placebo for 48 weeks to see if it could slow muscle decline. The trial was terminated early, so final results…
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:55 UTC